Merck has announced the expansion of its BioReliance® biosafety testing laboratory in Singapore, enhancing the Asia-Pacific (APAC) region’s biopharma quality control capabilities. This expansion, which increases the lab’s size to over 1,000 square metres, introduces the first combined Cell Line Characterisation and GMP Next-Generation Sequencing (NGS) facility in APAC, allowing for advanced local testing and reduced reliance on Western supply chains.
The expansion is a strategic move to bolster the region’s self-reliance in drug development amidst global trade uncertainties. By localising these capabilities, Merck aims to accelerate development timelines and improve operational efficiency for biopharma customers in the region. Paolo Carli, Head of Advanced Solutions for Merck’s Life Science business, stated, “This investment underscores Merck’s commitment to empowering medicine makers by providing industry-leading analytical and biosafety testing services and technical expertise.”
The Singapore lab will also incorporate advanced molecular methods, including the Blazar® platform for rapid virus detection, supporting the industry’s shift towards animal-free testing. This aligns with the 3Rs principle—Replacement, Reduction, and Refinement of animal use.
Goh Wan Yee, Senior Vice President and Head of Healthcare at the Singapore Economic Development Board, expressed optimism about the expansion, noting its potential to strengthen Singapore’s biopharma ecosystem and enhance local workforce capabilities.
Opened in 2018, the Singapore BioReliance® lab’s expansion is part of Merck’s broader strategy to support APAC’s dynamic life science ecosystem and drive scientific progress.
